5Pritzker KH. Cancer biomarkers : easier said than done. Clin Chem, 2002,48: 1147- 1150.
6Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use tumor markers in the clinic. Washington DC: AACC Press,2002.20-25
8Lakhani SR, Ashworth A. Microarray and histo-pathological analysis of tumours:the future and the past? Nature Rev Cancer, 2001,1:151-157.
9Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer benign breast disease and normal breast tissue. Breast Cancer Res Treat, 1996,40:171- 178.
10Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer, 2003,3:267-275.
6Oltrona L, Ardissino D, Medini P A, et al. C-reactiveprotein elevation and early outcome in patients with unstable angina pectoris[ J]. Am J Cardiol,1997,80(8) :1002-1006.
7Kristensen SD, Andersen HR, Falk E. What an interventional cardiologist should known about the pathophysiology of acute myocardial infarction [ J ]. Semin Interv Cardiol, 1999,4 ( 1 ) : 11-16.
8RICHARDS A M,NICHOLLS M G,ESPINER E A,et al.B-type nat riureticpeptide and ejection fraction for prognosis after myocardial infarction[J].Circulation,2003,107(22):2786-2792.
9TALWAR S,SQUIRE I B,DOWNIE P F,et al.Profile of plasma NT-proBNP following acute myocardial infarction;correlation with left wentricular systolic dyfunction[J].Eur Heart J,2000,21(18):1514-1521.
